Kenvue Inc. (NYSE:KVUE) Shares Purchased by Northern Trust Corp

Northern Trust Corp boosted its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 15.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,948,704 shares of the company's stock after acquiring an additional 2,796,306 shares during the period. Northern Trust Corp owned 1.09% of Kenvue worth $447,255,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its stake in Kenvue by 3.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock valued at $5,249,665,000 after purchasing an additional 8,211,748 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Kenvue by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock worth $4,665,908,000 after buying an additional 1,636,741 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock valued at $2,085,070,000 after buying an additional 10,682,003 shares in the last quarter. Geode Capital Management LLC grew its position in Kenvue by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company's stock worth $980,989,000 after acquiring an additional 1,391,854 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in Kenvue by 61.5% during the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after acquiring an additional 16,269,721 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Up 0.1 %

NYSE KVUE traded up $0.02 on Friday, reaching $23.98. 14,097,083 shares of the stock traded hands, compared to its average volume of 17,031,835. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a fifty day moving average price of $23.08 and a 200-day moving average price of $22.49. The company has a market cap of $46.01 billion, a price-to-earnings ratio of 45.25, a PEG ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.42%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue's payout ratio is 154.72%.

Analysts Set New Price Targets

KVUE has been the subject of several analyst reports. Canaccord Genuity Group raised their price objective on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Barclays dropped their price objective on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research note on Monday, April 14th. Royal Bank of Canada reissued a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. UBS Group cut their price target on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Finally, Redburn Atlantic assumed coverage on shares of Kenvue in a research report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective on the stock. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Kenvue currently has a consensus rating of "Hold" and an average price target of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.